These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 31638339)
1. Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells. Pietraszek-Gremplewicz K; Simiczyjew A; Dratkiewicz E; Podgórska M; Styczeń I; Matkowski R; Ziętek M; Nowak D J Cell Mol Med; 2019 Dec; 23(12):8453-8463. PubMed ID: 31638339 [TBL] [Abstract][Full Text] [Related]
2. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment. Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948 [TBL] [Abstract][Full Text] [Related]
3. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status. Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424 [TBL] [Abstract][Full Text] [Related]
4. Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells' Invasive Abilities. Simiczyjew A; Pietraszek-Gremplewicz K; Dratkiewicz E; Podgórska M; Matkowski R; Ziętek M; Nowak D Front Pharmacol; 2019; 10():1116. PubMed ID: 31649529 [TBL] [Abstract][Full Text] [Related]
5. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486 [TBL] [Abstract][Full Text] [Related]
6. [Study of motogenic signal in human melanoma cells]. Kenessey I Magy Onkol; 2011 Mar; 55(1):55-8. PubMed ID: 21617791 [TBL] [Abstract][Full Text] [Related]
7. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Matsushita R; Mataki H; Mizuno K; Okamoto Y; Seki N J Hum Genet; 2017 Jan; 62(1):113-121. PubMed ID: 27169691 [TBL] [Abstract][Full Text] [Related]
8. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889 [TBL] [Abstract][Full Text] [Related]
9. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904 [TBL] [Abstract][Full Text] [Related]
10. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397 [TBL] [Abstract][Full Text] [Related]
11. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities. Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282 [TBL] [Abstract][Full Text] [Related]
12. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. Steinway SN; Dang H; You H; Rountree CB; Ding W PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702 [TBL] [Abstract][Full Text] [Related]
13. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression. Molnár E; Garay T; Donia M; Baranyi M; Rittler D; Berger W; Tímár J; Grusch M; Hegedűs B Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514305 [TBL] [Abstract][Full Text] [Related]
14. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768 [TBL] [Abstract][Full Text] [Related]
15. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986 [TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490 [TBL] [Abstract][Full Text] [Related]
17. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. Mataki H; Seki N; Chiyomaru T; Enokida H; Goto Y; Kumamoto T; Machida K; Mizuno K; Nakagawa M; Inoue H Int J Oncol; 2015 Mar; 46(3):1039-50. PubMed ID: 25522678 [TBL] [Abstract][Full Text] [Related]
18. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103 [TBL] [Abstract][Full Text] [Related]
19. Casticin Inhibits A375.S2 Human Melanoma Cell Migration/Invasion through Downregulating NF-κB and Matrix Metalloproteinase-2 and -1. Wu ZY; Lien JC; Huang YP; Liao CL; Lin JJ; Fan MJ; Ko YC; Hsiao YP; Lu HF; Chung JG Molecules; 2016 Mar; 21(3):384. PubMed ID: 27007357 [TBL] [Abstract][Full Text] [Related]